Abbott Laboratories: A healthy dose - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Abbott Laboratories: A healthy dose

Jul 26, 2000

Abbott Laboratories (India), the 51.5% Indian subsidiary of Abbott USA has reported impressive results for the first quarter ended June 2001. Pre–tax profits have jumped almost 70% on the back of a 18.5% jump in the topline. The company has however not provided for the part of the deferred revenue expenditure, which was incurred when it paid of the workers of its Kurla plant who took a VRS when it shut down the plant. The balance meant to be written off amounts to Rs 22.28 m.

(Rs m)1QFY001QFY01Change
Sales 278 330 18.5%
Other Income 1 1 3.9%
Expenditure 260 309 18.8%
Operating Profit (EBDIT) 19 21 13.2%
Operating Profit Margin (%)6.7%6.4% 
Interest 7 1  
Depreciation 2 2 18.0%
Profit before Tax111869.4%
Other Adjustments   
Tax  2  
Profit after Tax/(Loss) 11 16 51.0%
Net profit margin (%)3.9%5.0% 
No. of Shares (m) (eoy)2.62.6 
Diluted no. of shares (m)2.62.6 
Diluted Earnings per share*16.725.1 
*(annualised)   

Abbott India, is active in the areas of anti–infectives, dermatological (skin infection), anti–diarrhoeal and gastro–intestinal apart from a portfolio of hospital products and nutritional products. The company has introduced Hytrin in India. The product has captured over 55% market share and has been growing at over 50% over the last two years. The company’s Claribid (used in cases of upper respiratory tract infection) also has been growing at over 40% and enjoys a 35% market share.

The company has also been restructuring its operations over the last three years. And the benefits of the restructuring are being reflected in the growth in pre–tax figures.

If one were to exclude the write off of deferred revenue expenditure, the current stock price of Rs 401 implies an earning multiple of around 16 times.

Equitymaster requests your view! Post a comment on "Abbott Laboratories: A healthy dose". Click here!

  

More Views on News

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

Block Deal Disappoints Max Healthcare Shareholders. Stock Falls 6% (Views On News)

Sep 30, 2021

The divestment of 6.6% stake by the promoter is considered to be one of the largest block deals of the market.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for (Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

5 Indian Companies Embracing Blockchain Technology (Views On News)

Nov 23, 2021

Blockchain adoption in India was slow in the past. Now, the technology is being well received.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK PHARMACIA HEALTH.

  • Track your investment in PHARMACIA HEALTH. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MARKET STATS